The FDA's approval of a new peripheral arterial disease (PAD) treatment from Endologix marks a significant milestone in addressing this prevalent condition. PAD affects millions of people worldwide, and this approval provides healthcare professionals with an additional treatment option to improve patient outcomes. Fast Five hosts Sean Whooley and Danielle Kirsh explain what the device is and how it works to improve patient outcomes. 

Surmodics recently received FDA 510(k) clearance for its Pounce LP thrombectomy system. The company designed Pounce for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. Whooley details the optimism from executives and when the company expects to initiate a limited market evaluation.

The launch of Stat Health's in-ear wearable device that measures blood flow introduces an exciting advancement in remote health monitoring. This innovative wearable technology provides individuals with a convenient and non-invasive means of tracking their blood flow, potentially enabling early detection of circulatory issues or abnormalities. Whooley and Kirsh discuss the technology in the wearable and why the company chose the ear for the wearable technology.

Cala's launch of a next-generation wearable device for essential tremor and Parkinson's therapy represents a significant advancement in non-invasive treatment options for the company, complementing its existing Cala Trio device. Whooley explains how the technology works and differs from the gold standard of care.

A recent study supporting Philips' direct-to-angio stroke pathway highlights the potential for innovative care models to improve stroke outcomes. The Fast Five hosts explain the study's findings.

Check out the show notes at MassDevice.com/podcast.

Ver todos los episodios